Biosimilars and Biologics in Medicare Part D: MedPAC briefing deck Via @medicarepayment #pharma #biotech goo.gl/awzqFL
Drug Pricing Reform: Understanding Indication Spec…
posted on September 20, 2016 by
Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals #pharma #biotech #drugs… twitter.com/i/web/status/7…
Biologics and Biosimilars: Backgrounder on FDA reg…
posted on September 15, 2016 by
Biologics and Biosimilars: Backgrounder on FDA regulatory issues, price comparisons, approvals goo.gl/qG2Twj #biotech #pharma
Drug companies offer money back guarantees for hig…
posted on August 14, 2016 by
Drug companies offer money back guarantees for high-cost, cutting-edge therapies #pharma #biotech flip.it/oLzNSO
Drug Development, Drug Pricing Dynamics, Supply Ch…
posted on June 16, 2016 by
Drug Development, Drug Pricing Dynamics, Supply Chain: Overview by MedPAC medpac.gov/documents/fact… #pharma #drugs #biotech #pharmacy
Medicare Prescription Drug Spending: Overview by M…
posted on June 16, 2016 by
Medicare Prescription Drug Spending: Overview by MedPAC. medpac.gov/documents/fact… #pharma #drugs #biotech
Medicare, Oncology, and Drugs: MedPAC deck on Part…
posted on April 14, 2016 by
Medicare, Oncology, and Drugs: MedPAC deck on Part B payment reforms. goo.gl/PJQGra #cancer #biotech #pharma
Health Insurers’ Perspectives on the Orphan Drug P…
posted on December 24, 2013 by
Health Insurers’ Perspectives on the Orphan Drug Pipeline. goo.gl/c7v0HQ #FDA #Pharma #Drugs #Biotech
Economics of Biosimilars: Biologic drug market mak…
posted on November 21, 2013 by
Economics of Biosimilars: Biologic drug market makes entry attractive but very risky. ahdbonline.com/issues/2013/se… #FDA #pharma #biotech
RT @AlecGaffney: Morning! HUGE edition of Regulato…
posted on November 11, 2013 by
RT @AlecGaffney: Morning! HUGE edition of Regulatory Recon, with all the #Pharma, #MedDevice, #Biotech and #FDA news you can handle: ow.ly/qH8ZN
